^
    1d
    Medical Cannabis During Chemoradiation for Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=30, Completed, Albert Einstein College of Medicine | Active, not recruiting --> Completed | Trial primary completion date: Jan 2026 --> Jul 2025
    Trial completion • Trial primary completion date
    1d
    Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P3, N=290, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • fluorouracil topical
    1d
    STC-15-24202: STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers (clinicaltrials.gov)
    P1/2, N=188, Recruiting, STORM Therapeutics LTD | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • STC-15
    1d
    A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=167, Recruiting, Shanghai Henlius Biotech | N=90 --> 167 | Trial completion date: Jul 2028 --> Jan 2029
    Enrollment change • Trial completion date
    |
    Hetronifly (serplulimab) • pimurutamab (HLX07) • HLX43
    2d
    Pre-existing TCR clones drive major pathological responses in HNSCC patients treated with dual immune checkpoint inhibitors. (PubMed, Clin Cancer Res)
    Dual ICI drives MPR predominantly through the adaptivity and functional reprogramming of pre-existing immunity. Successful therapy relies on a coordinate repertoire response that promotes transition of putative tumor-reactive super-expanders into productive functional states. TRS-integrated TAI provides a high-throughput framework incorporating clonal dynamics and functional reprogramming to predict therapeutic efficacy.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    2d
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    2d
    (BLOOM): Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy (clinicaltrials.gov)
    P1/2, N=55, Not yet recruiting, University of Chicago | Initiation date: Jan 2026 --> Dec 2026
    Trial initiation date
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    2d
    A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, University of Chicago | Initiation date: Jan 2026 --> Dec 2026
    Trial initiation date • Minimal residual disease
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • NavDx®
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    2d
    Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer (clinicaltrials.gov)
    P2, N=38, Recruiting, University of Chicago | Suspended --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • volrustomig (MEDI5752)
    2d
    TARGET-HPV: TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers (clinicaltrials.gov)
    P1/2, N=98, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel
    2d
    GRWD5769-ST-01: A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies (2023-504845-30-00)
    P1/2, N=130, Recruiting, Grey Wolf Therapeutics Limited | N=65 --> 130
    Enrollment change
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    Libtayo (cemiplimab-rwlc) • GRWD5769
    2d
    MC2TCR: MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Erasmus Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    azacitidine